- $352.54m
- $363.38m
Brief: CytoDyn Appoints Seenu Srinivasan As Executive Director Of CMC Regulatory Affairs
Brief: CytoDyn Receives FDA Guidance For Its HIV BLA Dose Justification Report
Brief: Cytodyn Receives Clearance From Brazil’S Anvisa To Commence Phase 3 Trial For Severe Covid-19 Patients
Biotech firm CytoDyn calls activists' board nomination notice invalid -sources (updated)
Biotech firm CytoDyn calls activists' board nomination notice invalid -sources
Brief: Cytodyn Announces Preliminary Results From 30 Mtnbc Patients Treated With Leronlimab. Decreases In Camls After 4 Doses Of Leronlimab Were Identified In Over 70% Of Patients And Were Associated With A 450% Significant Increase In Overall Survival At 12-Month Analysis
Brief: Cytodyn Inc. Announces Positive Preliminary Results Of Unblinded Data From Long-Haulers Trial Showing Greater Improvement In Leronlimab Group Over Placebo In 18 Of 24 Symptoms
Brief: CytoDyn To Hold Webcast On June 21 To Discuss Unblinded Data From Covid-19 Long-Haulers Trial And Other Developments
Brief: Cytodyn Receives First Purchase Order From Chiral Pharma Corporation For Use Of Leronlimab Under CSP For Covid-19 Patients In The Philippines
Brief: Cytodyn Says Antonio Migliarese Promoted To CFO
Brief: Cytodyn Inc Says Agreement To Partner With Albert Einstein Israelite Hospital In São Paulo, Brazil For Two COVID-19 Trials
Brief: Cytodyn Says Chiral Pharma Corporation To Provide Up To 200,000 Vials Of Leronlimab To Philippines
Brief: Cytodyn Inc Says COVID-19 Long-Haulers Study Is Now Fully Enrolled
Brief: Cytodyn Signs Exclusive Supply And Distribution Agreement With Biomm S.A. In Brazil For Covid-19 And All Other Leronlimab Indications
Brief: Cytodyn Files New Protocol With U.S. FDA For 4 Doses Of Leronlimab For Critically Ill COVID-19 Patients
Brief: Cytodyn’S Leronlimab Decreased Mortality At 14 Days By 82% With Statistically Significant P-Value Of 0.0233 Amongst Critically Ill Covid-19 Patients
Brief: CytoDyn To File Accelerated Rolling Review With MHRA And Interim Order With Health Canada For COVID-19
Brief: CytoDyn Says Leronlimab Trial Demonstrated 24% Reduction In Mortality For Critically Ill COVID-19 Patients
Brief: Cytodyn Inc Says Plans To Initiate A Registration-Directed Study Of Leronlimab Monotherapy Indication